Cornea Damage Articles & Analysis
4 news found
(“BRIM,” TPEx 6885) is pleased to announce that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for BRM424 in the treatment of neurotrophic keratitis (NK), a rare degenerative eye disease which causes very severe cornea damage and can lead to loss of sight. Dr. Haishan Jang, Chairwoman and CEO of BRIM ...
” BRM421 is a novel, first-in-class regenerative peptide therapy which, if successful, could offer patients full relief of symptoms plus repair the damage to the cornea. BRM421 is derived from BRIM’s proprietary, stem cell regenerative PEDF-derived Short Peptides (PDSPs), which can also be applied across multiple therapy areas and indications. In the ...
BRM421 is a novel, first-in-class regenerative peptide therapy which, if successful, could offer patients complete relief from dry eye symptoms by stimulating the proliferation and differentiation of stem cells to repair damage to the cornea. BRM421 was developed using BRIM’s proprietary stem cell regenerative Pigment Epithelium-Derived Factor (PEDF) ...
The functional domain of PEDF chosen to generate PDSPs can be used to treat dry eye disease by speeding up the cornea repair process through stimulation of corneal stem cell proliferation and differentiation, anti-inflammation and meibomian gland recovery.?? ...